A Side-by-side Analysis of Juno Therapeutics, Inc. (JUNO) and Pacific Biosciences of California, Inc. (PACB)

Juno Therapeutics, Inc. (NASDAQ:JUNO) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) are the two most active stocks in the Biotechnology industry based on today’s trading volumes. Investors are clearly interested in the two names, but is one a better choice than the other? We will compare the two companies across growth, profitability, risk, valuation, and insider trends to answer this question.

Profitability and Returns

Growth in and of itself is not necessarily valuable, and it can even be harmful to shareholders if companies overinvest in unprofitable projects in pursuit of that growth. We will use Return on Investment (ROI), which adjust for differences in capital structure, as measure of profitability and return. JUNO’s ROI is -23.00% while PACB has a ROI of -70.70%. The interpretation is that JUNO’s business generates a higher return on investment than PACB’s.

Cash Flow 

Cash is king when it comes to investing. JUNO’s free cash flow (“FCF”) per share for the trailing twelve months was -0.57. Comparatively, PACB’s free cash flow per share was -0.17. On a percent-of-sales basis, JUNO’s free cash flow was -0.08% while PACB converted -0.02% of its revenues into cash flow. This means that, for a given level of sales, PACB is able to generate more free cash flow for investors.

Liquidity and Financial Risk

Analysts look at liquidity and leverage ratios to assess how easily a company can cover its liabilities. JUNO has a current ratio of 5.10 compared to 3.70 for PACB. This means that JUNO can more easily cover its most immediate liabilities over the next twelve months. JUNO’s debt-to-equity ratio is 0.03 versus a D/E of 0.11 for PACB. PACB is therefore the more solvent of the two companies, and has lower financial risk.


JUNO trades at a forward P/B of 4.67, and a P/S of 54.92, compared to a forward P/B of 4.68, and a P/S of 6.68 for PACB. JUNO is the cheaper of the two stocks on book value basis but is expensive in terms of P/E and P/S ratio. Given that earnings are what matter most to investors, analysts tend to place a greater weight on the P/E.

Analyst Price Targets and Opinions

Just because a stock is cheaper doesn’t mean there’s more value to be had. In order to assess value we need to compare the current price to where it’s likely to trade in the future. JUNO is currently priced at a 17.23% to its one-year price target of $35.75. Comparatively, PACB is -6.39% relative to its price target of $5.95. This suggests that PACB is the better investment over the next year.

The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 1.90 for JUNO and 1.80 for PACB, which implies that analysts are more bullish on the outlook for JUNO.

Risk and Volatility

To gauge the market risk of a particular stock, investors use beta. Stocks with a beta above 1 are more volatile than the market as a whole. Conversely, a beta below 1 implies below average systematic risk. PACB’s beta is 2.09.

Insider Activity and Investor Sentiment

Analysts often look at short interest, or the percentage of a company’s float currently being shorted by investors, to aid in their outlook for a particular stock. JUNO has a short ratio of 6.29 compared to a short interest of 12.61 for PACB. This implies that the market is currently less bearish on the outlook for JUNO.


Pacific Biosciences of California, Inc. (NASDAQ:PACB) beats Juno Therapeutics, Inc. (NASDAQ:JUNO) on a total of 5 of the 11 factors compared between the two stocks. PACB generates a higher return on investment and has a higher cash conversion rate.  PACB is more undervalued relative to its price target. Finally, GILD has better sentiment signals based on short interest.

Previous ArticleNext Article

Related Post

The Charles Schwab Corporation (SCHW): Are There S... The Charles Schwab Corporation (NYSE:SCHW) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a ma...
Array BioPharma Inc. (ARRY) Forming A Pattern Of M... It is interesting to note that Array BioPharma Inc. (NASDAQ:ARRY) is active and made a solid movement in the last trading day. Now trading with a mark...
Looking at the Big Picture for Southwest Airlines ... Southwest Airlines Co. (NYSE:LUV) is an interesting stock at present. Now trading with a market value of 34.03B, the company has a mix of catalysts an...
Taking a Look at the Operational Data for Cognex C... Cognex Corporation (NASDAQ:CGNX) is on our radar right now but there could still be some opportunities on the horizon. Now trading with a market value...
Noble Corporation plc (NE): More In-Depth Monitori... Noble Corporation plc (NYSE:NE) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participants trying...